Organization type
- Private research organization
Early phases
- Biomarker identification
-
Omics
- Genomics
- Proteomics
- Transcriptomics
- Target identification – new biological hypothesis
- Target validation – Hypothesis verification
Screening
-
Assay development
- In vitro screening models
- In vivo screening models
-
Fragment based screening
- Virtual screening
- Screening and high throughput screening using small molecules (including natural product, DNA encoded libraries and fragment libraries)
Optimization phases
- In vitro biochemical models(including assay/model development and testing)
- In vitro cellular and organotypic 3D models (including assay/model development and testing)
- In vivo animal models (including assay/model development and testing)
-
Mechanism of action (MoA) assessment
- Omics profiling
-
Preclinical phase (including assay/model development and testing)(non-regulatory and regulatory)
- ADME / DMPK
- Toxicology
Functional areas
- Bioinformatics
-
Molecular and cellular biology
- Flow cytometry
- Imaging / High content screening
- Protein expression / purification
- qPCR
- RNAseq
- Sequencing
- Structural biology
Terapeutic areas
- Autoimmunity / Inflammation
- Cancer
- Infectious diseases
- Rare diseases
Additional activities
- Consulting services
- CROs providing no-regulatory and regulatory services for drug discovery
- Government initiatives supporting drug and research collaborations